Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity

Cancer

Volumn 106, Issue 6, 2006, Pages 1269-1275

  Lin, Chia Chi ^a,b   Hsu, Chih Hung ^a,b   Huang, Chao Yuan ^a   Cheng, Ann Lii ^a,b   Chen, Jun ^a   Vogelzang, Nicholas J ^c   Pu, Yeong Shiau ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NEVADA CANCER INSTITUTE   (United States)

Author keywords

Bladder neoplasms; Carcinoma; Cytotoxic; Myelosuppression; Toxicity; Transitional cell

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLADDER TUMOR; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; UROTHELIUM; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33644838678     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21738     Document Type: Article

References (20)

1. Roth BJ, Bajorin DF. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol. 1995;153:894-900.
2. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1997;15:2564-2569.
3. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-1055.
4. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
5. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-3181.
6. Hsu CH, Chen J, Wu CY, Cheng AL, Pu YS. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma. Anticancer Res. 2001;21:711-715.
7. Cheng AL, Yeh KH, Lin JT, Hsu C, Liu MY. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)-a very effective regimen with good patients' compliance for advanced gastric cancer. Anticancer Res. 1998;18:1267-1272.
8. Lin CC, Hsu CH, Chen J, Tsai TC, Cheng AL, Pu YS. A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer. Anticancer Res. 2001;21:1385-1390.
9. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407-1418.
10. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA. 1986;83:8923-8925.
11. Johnston PG, Geoffrey F, Drake J, Voeller D, Grem JL, Allegra CJ. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. Eur J Cancer. 1996;32A:2148-2154.
12. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res. 1999;5:2620-2628.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
14. Shuster JJ. Median follow-up in clinical trials. J Clin Oncol. 1991;9:191-192.
15. Yeh KH, Yeh SH, Chang YS, Cheng AL. Minimal toxicity to myeloid progenitor cells of weekly 24-hr infusion of high-dose 5-fluorouracil: direct evidence from colony forming unit-granulocyte and monocyte (CFU-GM) clonogenic assay. Pharmacol Toxicol. 2000;86:122-124.
16. Kosmidis PA, Bacoyiannis C, Fountzilas G, et al. 5-Fluorouracil, interferon-alpha-2b and cisplatin (FAP) for advanced urothelial cancer. A phase II study. Hellenic Co-operative Oncology Group. Ann Oncol. 1997;8:373-378.
17. Bazarbashi S, Pai C, Raja MA, Rahal M, Ezzat A, Hanash K. Phase II trial of cisplatin, 5-fluorouracil, and interferon-alpha-2B as first line treatment of advanced urothelial cancer. Urol Oncol. 2003;21:185-189.
18. Siefker-Radtke AO, Millikan RE, Tu SM, et al. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vlnblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20:1361-1367.
19. Oh WK, Manola J, Richie JP, Loughlin KR, Kantoff PW. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. Cancer. 1999;86:1329-1334.
20. Kish JA, Wolf MK, Schellhammer PF, Hussain MH, Einstein AB, Crawford ED. Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial. Am J Clin Oncol. 1997;20:327-330.